FDC liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
9.77×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.11×3.11×3.00×3.58×3.42×
2.13×2.13×1.96×2.33×2.37×
611521536475481
763768724802755
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

FDC₹377.15

FDC Limited

· Pharma & Health
₹ CrorePeersIOLCPMOREPENLABINNOVACAPORCHPHARMASENORESGUJTHEMRPGLIFESANOFIMcap ₹6,140 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)————9.77
Current Ratio3.423.583.003.113.11
Quick Ratio2.372.331.962.132.13
Cash, Equiv & ST Investments481.2475.4536.1521.4611.1
Working Capital755.1801.8723.6768.4763.3
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.